WO2002072114A3 - Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent - Google Patents

Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent Download PDF

Info

Publication number
WO2002072114A3
WO2002072114A3 PCT/US2001/047273 US0147273W WO02072114A3 WO 2002072114 A3 WO2002072114 A3 WO 2002072114A3 US 0147273 W US0147273 W US 0147273W WO 02072114 A3 WO02072114 A3 WO 02072114A3
Authority
WO
WIPO (PCT)
Prior art keywords
extracts
anxiolytic
sedative agent
magnoliaceae
honokiol
Prior art date
Application number
PCT/US2001/047273
Other languages
French (fr)
Other versions
WO2002072114A2 (en
Inventor
Martin Stogniew
Robert Garrison Jr
Original Assignee
Next Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Pharmaceuticals Inc filed Critical Next Pharmaceuticals Inc
Priority to CA2431011A priority Critical patent/CA2431011C/en
Priority to GB0313167A priority patent/GB2385524B/en
Publication of WO2002072114A2 publication Critical patent/WO2002072114A2/en
Publication of WO2002072114A3 publication Critical patent/WO2002072114A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

The invention relates to compositions and methods for preventing, treating, or managing sleeplessness, restlessness, weight gain including weight gain due to stress or lack of sleep, or all three comprising the administration of a prophylactically and therapeutically effective amount of Magnoliaceae plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the composition have comprise at least two compounds selected from magnolol, honokiol, and magnoflorine. Alternatively, the compositions may also comprise about 2% honokiol by weight of the composition.
PCT/US2001/047273 2000-12-15 2001-12-03 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent WO2002072114A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2431011A CA2431011C (en) 2000-12-15 2001-12-03 Compositions and methods of use for extracts of magnoliaceae plants
GB0313167A GB2385524B (en) 2000-12-15 2001-12-03 Compositions and methods of use for extracts of magnoliaceae

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25540200P 2000-12-15 2000-12-15
US60/255,402 2000-12-15

Publications (2)

Publication Number Publication Date
WO2002072114A2 WO2002072114A2 (en) 2002-09-19
WO2002072114A3 true WO2002072114A3 (en) 2003-01-23

Family

ID=22968165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047273 WO2002072114A2 (en) 2000-12-15 2001-12-03 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent

Country Status (5)

Country Link
US (3) US6582735B2 (en)
AU (1) AU2001100681A4 (en)
CA (1) CA2431011C (en)
GB (1) GB2385524B (en)
WO (1) WO2002072114A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
WO2003052681A1 (en) * 2001-12-17 2003-06-26 International Barcode Corporation Double-sided bar code doubling as a single bar code
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
US7595065B2 (en) * 2002-06-25 2009-09-29 Wm. Wrigley Jr. Company Breath freshening and oral cleansing products with synergistic combinations of magnolia bark extract and essential oils
US7632525B2 (en) * 2002-06-25 2009-12-15 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
CN1723011A (en) * 2002-06-25 2006-01-18 Wm·雷格利Jr·公司 Breath freshening and oral cleansing product with magnolia bark extract
WO2004019802A2 (en) * 2002-08-27 2004-03-11 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product using carvacrol
DE60333196D1 (en) * 2002-08-27 2010-08-12 Wrigley W M Jun Co AIRBORNE AND MOUTHPROOF PRODUCT USING CARDAMOM L
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
US20060018975A1 (en) * 2004-07-20 2006-01-26 Talbott Shawn M Methods and compositions for weight management and mood enhancement
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
RU2398594C2 (en) * 2005-12-02 2010-09-10 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Confectionery compositions containing magnolia bark extract
CN101321513A (en) * 2005-12-02 2008-12-10 Gic创新公司 Vehicles for oral care with magnolia bark extract
CN101321560B (en) * 2005-12-02 2012-10-31 Gic创新公司 Chewable compositions with fast release magnolia bark extract
KR100808972B1 (en) * 2006-02-08 2008-03-04 한국생명공학연구원 A pharmaceutical composition containing obovatol as an active ingredient for prevention and treatment neurodegenerative diseases
US20080226582A1 (en) * 2007-03-13 2008-09-18 Deok Hoon Park Composition for improving atopic dermatological diseases comprising magnolol and honokiol
CA2684601C (en) 2007-04-19 2014-04-29 Mary Kay Inc. Cosmetic methods of treating skin with magnolia and citrus grandis extracts containing compositions
US20100003351A1 (en) * 2008-07-02 2010-01-07 Jaffe Russell M Compositions comprising rhodiola rosea and methods of use thereof
US9180154B2 (en) * 2009-11-05 2015-11-10 Arizona Health Consulting Group, Llc Method of manufacturing magnoliidae compounds
KR101327282B1 (en) * 2012-02-16 2013-11-08 초당약품공업 주식회사 Improved pharmaceutical preparation containing Yellow-popular bark extract as active ingredient
KR102163313B1 (en) * 2012-05-29 2020-10-08 유니젠, 인크. Compositions and methods for managing weight
CA2995834A1 (en) 2015-08-17 2017-02-23 St Ip Holding Ag Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof
PL3344273T3 (en) 2015-08-31 2020-06-01 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
CN107319523A (en) * 2017-06-23 2017-11-07 天津金匮堂生物科技有限公司 A kind of insufficiency of heart yin that improves causes health products of insomnia and preparation method thereof
IT201900008259A1 (en) * 2019-06-06 2020-12-06 Nutrilinea S R L COMPOSITION INCLUDING EXTRACTS OF EUCOMMIA ULMOIDES, CROCUS SATIVUS AND MAGNOLIA OFFICINALIS AND ITS USE IN THE TREATMENT OF SLEEP DISORDERS
KR102287719B1 (en) * 2020-01-08 2021-08-09 삼육대학교산학협력단 Composition for inducing and improving sleep comprising extracts or fractions of Magnoliae flos
CN113456544B (en) * 2020-11-18 2022-07-29 太和康美(北京)中医研究院有限公司 Magnolia officinalis flower extract and preparation method and application thereof
CN113509528A (en) * 2021-04-23 2021-10-19 花安堂生物科技集团有限公司 Composition and sleep-aiding product containing magnolia sieboldii extract
CN113288834A (en) * 2021-04-23 2021-08-24 花安堂生物科技集团有限公司 New application of Magnolia sieboldii extract
CN113476317A (en) * 2021-06-30 2021-10-08 花安堂生物科技集团有限公司 Antioxidant liposome and preparation method thereof
CA3220080A1 (en) * 2021-07-05 2023-01-12 David Wilfred Lafond Composition for promoting relaxation and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083033A (en) * 1994-06-17 1996-01-09 Yakult Honsha Co Ltd Suppressant for cholesterol absorption
JPH10338631A (en) * 1997-06-04 1998-12-22 Tsumura & Co Anti-anxiety agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5995229A (en) 1982-11-24 1984-06-01 Tsumura Juntendo Inc Novel hydroxybiphenyl compound
JPS6046086B2 (en) 1982-12-28 1985-10-14 一丸ファルコス株式会社 Cosmetics containing goshiyuyu extract
JPS59130811A (en) * 1983-01-17 1984-07-27 Nitto Electric Ind Co Ltd Plaster base for pharmaceutical preparation of adherent application
JPS6042485A (en) * 1983-08-17 1985-03-06 Osaka Chem Lab Antioxidant
JPS615024A (en) * 1984-06-18 1986-01-10 Takeda Chem Ind Ltd Preparation of crude drug pharmaceutical
JPH01102007A (en) 1987-10-14 1989-04-19 Taiyo Kagaku Co Ltd Insect pest controlling agent
JPH0398562A (en) 1989-09-11 1991-04-24 Taiyo Kagaku Co Ltd Beverage composition
JPH03123734A (en) * 1989-10-05 1991-05-27 Kuraray Co Ltd Antipollakiuria agent
ES2095945T3 (en) * 1990-08-16 1997-03-01 Iatron Lab ACTIVATOR OF THE CENTRAL NERVOUS SYSTEM.
JPH04108736A (en) * 1990-08-24 1992-04-09 Nagakura Seiyaku Kk Virus-genomic inactivating-carcinogenic promotion inhibitor
JPH04154728A (en) * 1990-10-16 1992-05-27 Keijiyun Go Cathartic
JPH0798752B2 (en) * 1991-08-09 1995-10-25 株式会社ツムラ β-glucuronidase inhibitor
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1105557A (en) * 1994-10-11 1995-07-26 吴宏伟 Method for preparation of weight-loosing medicine and its products
DE19609736A1 (en) 1996-03-13 1997-09-18 Thomson Brandt Gmbh Detection circuit for pilot tones for tracking control in magnetic tape recordings
US5869540A (en) * 1996-03-29 1999-02-09 Smith; Walter P. Herbal treatments for improving skin appearance
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
JPH1017485A (en) 1996-07-02 1998-01-20 Hino Seiyaku Kk Antioxidant
JPH10194984A (en) 1997-01-07 1998-07-28 Hino Seiyaku Kk Carcinogenic virus activation suppressant
JP2000229869A (en) * 1999-02-09 2000-08-22 Nippon Synthetic Chem Ind Co Ltd:The Alpha-glucosidase inhibitor
KR100317112B1 (en) * 1999-03-18 2001-12-22 한영복 Pharmaceutical composition comprising mixed-extract of phellodendron cortex and anemarrhena rhizoma for alalgesic and anti-inflammation
US6210680B1 (en) * 1999-06-11 2001-04-03 Univera Pharmaceuticals, Inc. Method for the prevention and treatment of chronic venous insufficiency
WO2001045725A2 (en) * 1999-12-23 2001-06-28 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US6358540B1 (en) * 2000-11-07 2002-03-19 Ozog, Iii Stanley T. Herbal composition for treatment of tinnitus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083033A (en) * 1994-06-17 1996-01-09 Yakult Honsha Co Ltd Suppressant for cholesterol absorption
JPH10338631A (en) * 1997-06-04 1998-12-22 Tsumura & Co Anti-anxiety agent

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 1996-094111, XP002210437 *
DATABASE WPI Derwent World Patents Index; AN 1999-114788, XP002210436 *
HSIEH M.T. ET AL.: "Magnolol decreases body temperature by reducing 5-hydroxytryptamine release in the rat hypothalamus.", CLIN. EXP. PHARMACOL. PHYSIOL., vol. 25, no. 10, October 1998 (1998-10-01), pages 813 - 817, XP001098181 *
MARUYAMA Y. ET AL.: "Identification of Magnolol and Honokiol as anxiolytic agents in extracts of Saiboku-to, an oriental herbal medicine.", J. NAT. PROD., vol. 61, 1998, pages 135 - 138, XP002210434 *
MARUYAMA Y. ET AL.: "Overview of the pharmacological featurs of Honokiol.", CNS DRUG REVIEW., vol. 6, no. 1, April 2000 (2000-04-01), pages 35 - 44, XP001098195 *
TACHIKAWA E. ET AL.: "Effects of extracts and ingredients isolated from Magnolia obovata Thunberg on catecholamine secretion from bovine adrenal chromaffine cells.", BIOCHEMICAL PHARMACOLOGY., vol. 60, August 2000 (2000-08-01), pages 433 - 440, XP002210435 *
WATANABE K. ET AL.: "Studies on the active principles of Magnolia bark. Centrally cating musclse relaxant magnolol and honokiol.", JAP. J. PHARMACOL., vol. 25, no. 5, October 1975 (1975-10-01), pages 605 - 607, XP001098087 *

Also Published As

Publication number Publication date
WO2002072114A2 (en) 2002-09-19
GB0313167D0 (en) 2003-07-16
CA2431011A1 (en) 2002-09-19
AU2001100681A4 (en) 2006-11-02
US6582735B2 (en) 2003-06-24
GB2385524A (en) 2003-08-27
US20020076456A1 (en) 2002-06-20
US20030206975A1 (en) 2003-11-06
US20040228934A1 (en) 2004-11-18
CA2431011C (en) 2011-06-21
GB2385524B (en) 2005-07-27
US6814987B2 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
WO2002072114A3 (en) Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent
ATE180166T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING HERBAL ACTIVE ACTIVE INGREDIENTS, METHOD FOR THE PRODUCTION AND USE FOR MEDICAL AND VETERINAL PURPOSES
NO952863D0 (en) Fluoxetine Pharmaceutical Compositions
ATE412417T1 (en) TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND RELATED SKIN DISEASES
RU2002123048A (en) IMPROVED VEGETABLE COMPOSITION POSSESSING ANTI-ALLERGIC PROPERTIES AND METHOD FOR PRODUCING IT
CN104295052A (en) Environment-protecting flooring containing ceramic
BR9713363A (en) Epothilones c, d, e and f, preparation and compositions
WO2002092028A3 (en) Oral care compositions
WO2001068040A3 (en) The use of plant extracts and sugars to protect keratinous tissue
WO2003051380A3 (en) Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
UA66796C2 (en) Composition "profesol foamy" for treating radiation lesions of skin
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
WO2002091858A8 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
WO2001008671A3 (en) Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
MX2007000120A (en) Herbal composition.
ES2086274T1 (en) PREPARED FOR CRATEGUS SPECIES, MEDICINES, AND THEIR USE TO PREVENT Sudden Cardiac Death AS WELL AS CARDIOVASCULAR INJURIES CAUSED BY REPERFUSION.
WO2002062952A3 (en) Non-cytotoxic pap mutants
DE69626516D1 (en) Azadirachtin formulations and their preparation from seeds of the neem tree
FR2710844B1 (en) Composition for the treatment or prevention of herpes.
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
BR0106527A (en) Herbal compound for venous ulcer treatment
UA49159A (en) Composition intended for treating dermatological diseases
RO107191B1 (en) Vegetal powders composition, used in cosmetics
RU97115720A (en) TEA "NARKODEL" -BAD
GR1003099B (en) Substances of natural or synthetic origin, which belong to the groups of terpenoids, polyphenols and proanthocyanidins, used for the prevention and treatment of any type of hypercholesterolemia and lipids' disturbances, in humans and animals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 0313167

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20011203

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2431011

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002258363

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP